Last reviewed · How we verify
Alpha blocker
Alpha blocker, marketed by KYU-SUNG LEE, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Alpha blocker |
|---|---|
| Sponsor | KYU-SUNG LEE |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men (NA)
- Lumbar Spinal Fibrosis and TNF Alpha Inhibition (PHASE3)
- Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity (PHASE1)
- Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment (PHASE4)
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Ultrasound IPP to Predict Response to Medical Therapy in LUTS/BPH
- Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin (NA)
- Effect of Preoperative Alpha-blockers on Successful Insertion Ureteral Access Sheath and Reduce Ureteral Injury in Non-prestented Patients During RIRS. Assessment of Factors for Successful Ureteral Access Sheath Insertion.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |